Gemphire Therapeutics

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, Mich., Dec.  30, 2019  (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions.

Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals

ANN ARBOR, Mich., Dec.  06, 2019  (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all of the merger-related proposals, including: (i) the issuance of Gemphire common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated July 24, 2019, by and among Gemphire, GR Merger Sub Inc. and NeuroBo Pharmaceuticals, Inc. and the change of control of Gemphire resulting from the merger, (ii) a reverse stock split of Gemphire common stock, at a ratio of one new share for every 15 to 25 shares outstanding and (iii) changing the name of Gemphire from “Gemphire Therapeutics Inc.” to “NeuroBo Pharmaceuticals, Inc.”

Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals

Gemphire Therapeutics Inc (NASDAQ: GEMP) stock — which has been on a broader downtrend since mid-2017 — was advancing strongly Thursday.

Gemphire Flirts With $1 Level As Struggling Biotech Strikes Reverse Merger Deal

Gemphire Therapeutics (NASDAQ: GEMP) shares are trading lower after the company announced trial results for evaluating the safety, and tolerability of oral gemcabene.

Gemphire Therapeutics Falls 20% After Oral Cholesterol Drug Trial Results

My last two articles on Gemphire Therapeutics focused on the scientific and clinical errors that have delayed the clinical development of its lead investigative drug candidate, Gemcabene.

Gemphire And Gemcabene: The Orphan First Approach Is An Excellent Clinical Refocus

News for Gemphire Therapeutics Stock (GEMP)